Effectiveness of lopinavir/ritonavir on COVID-19-related pneumonia in a child with COVID-19-associated Kawasaki disease.
Identifieur interne : 000531 ( Main/Exploration ); précédent : 000530; suivant : 000532Effectiveness of lopinavir/ritonavir on COVID-19-related pneumonia in a child with COVID-19-associated Kawasaki disease.
Auteurs : Zerrin Orbak [Turquie] ; Fuat Laloglu [Turquie] ; Hulya Akat [Turquie]Source :
- Cardiology in the young [ 1467-1107 ] ; 2021.
Descripteurs français
- KwdFr :
- Ampicilline (usage thérapeutique), Antibactériens (usage thérapeutique), Anticoagulants (usage thérapeutique), Antiviraux (usage thérapeutique), Association médicamenteuse (MeSH), Azithromycine (usage thérapeutique), Enfant (MeSH), Facteurs immunologiques (usage thérapeutique), Humains (MeSH), Hydroxychloroquine (usage thérapeutique), Hypoxie (physiopathologie), Hypoxie (thérapie), Hypoxie (étiologie), Immunoglobulines par voie veineuse (usage thérapeutique), Lopinavir (usage thérapeutique), Maladie de Kawasaki (physiopathologie), Maladie de Kawasaki (traitement médicamenteux), Maladie de Kawasaki (étiologie), Mâle (MeSH), Oséltamivir (usage thérapeutique), Oxygénothérapie (MeSH), Poumon (imagerie diagnostique), Ritonavir (usage thérapeutique), Sulbactam (usage thérapeutique), Tomodensitométrie (MeSH), Énoxaparine (usage thérapeutique).
- MESH :
- imagerie diagnostique : Poumon.
- physiopathologie : Hypoxie, Maladie de Kawasaki.
- thérapie : Hypoxie.
- traitement médicamenteux : Maladie de Kawasaki.
- usage thérapeutique : Ampicilline, Antibactériens, Anticoagulants, Antiviraux, Azithromycine, Facteurs immunologiques, Hydroxychloroquine, Immunoglobulines par voie veineuse, Lopinavir, Oséltamivir, Ritonavir, Sulbactam, Énoxaparine.
- étiologie : Hypoxie, Maladie de Kawasaki.
- Association médicamenteuse, Enfant, Humains, Mâle, Oxygénothérapie, Tomodensitométrie.
English descriptors
- KwdEn :
- Ampicillin (therapeutic use), Anti-Bacterial Agents (therapeutic use), Anticoagulants (therapeutic use), Antiviral Agents (therapeutic use), Azithromycin (therapeutic use), COVID-19 (complications), COVID-19 (diagnostic imaging), COVID-19 (drug therapy), COVID-19 (physiopathology), COVID-19 Nucleic Acid Testing (MeSH), COVID-19 Serological Testing (MeSH), Child (MeSH), Drug Combinations (MeSH), Enoxaparin (therapeutic use), Humans (MeSH), Hydroxychloroquine (therapeutic use), Hypoxia (etiology), Hypoxia (physiopathology), Hypoxia (therapy), Immunoglobulins, Intravenous (therapeutic use), Immunologic Factors (therapeutic use), Lopinavir (therapeutic use), Lung (diagnostic imaging), Male (MeSH), Mucocutaneous Lymph Node Syndrome (drug therapy), Mucocutaneous Lymph Node Syndrome (etiology), Mucocutaneous Lymph Node Syndrome (physiopathology), Oseltamivir (therapeutic use), Oxygen Inhalation Therapy (MeSH), Ritonavir (therapeutic use), Sulbactam (therapeutic use), Tomography, X-Ray Computed (MeSH).
- MESH :
- chemical , therapeutic use : Ampicillin, Anti-Bacterial Agents, Anticoagulants, Antiviral Agents, Azithromycin, Enoxaparin, Hydroxychloroquine, Immunoglobulins, Intravenous, Immunologic Factors, Lopinavir, Oseltamivir, Ritonavir, Sulbactam.
- complications : COVID-19.
- diagnostic imaging : COVID-19, Lung.
- drug therapy : COVID-19, Mucocutaneous Lymph Node Syndrome.
- etiology : Hypoxia, Mucocutaneous Lymph Node Syndrome.
- physiopathology : COVID-19, Hypoxia, Mucocutaneous Lymph Node Syndrome.
- therapy : Hypoxia.
- COVID-19 Nucleic Acid Testing, COVID-19 Serological Testing, Child, Drug Combinations, Humans, Male, Oxygen Inhalation Therapy, Tomography, X-Ray Computed.
Abstract
The large outbreak of coronavirus disease 2019 (COVID-19) is spreading all over the world rapidly. There have recently been publications in the literature regarding the relationship between COVID-19 and Kawasaki disease, but there is no sufficient knowledge about the treatment and follow-up.
DOI: 10.1017/S1047951120004291
PubMed: 33183365
PubMed Central: PMC7737124
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effectiveness of lopinavir/ritonavir on COVID-19-related pneumonia in a child with COVID-19-associated Kawasaki disease.</title>
<author><name sortKey="Orbak, Zerrin" sort="Orbak, Zerrin" uniqKey="Orbak Z" first="Zerrin" last="Orbak">Zerrin Orbak</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Pediatrics, Ataturk University, Erzurum, Turkey.</nlm:affiliation>
<country xml:lang="fr">Turquie</country>
<wicri:regionArea>Department of Pediatrics, Ataturk University, Erzurum</wicri:regionArea>
<wicri:noRegion>Erzurum</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Laloglu, Fuat" sort="Laloglu, Fuat" uniqKey="Laloglu F" first="Fuat" last="Laloglu">Fuat Laloglu</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Pediatrics, Ataturk University, Erzurum, Turkey.</nlm:affiliation>
<country xml:lang="fr">Turquie</country>
<wicri:regionArea>Department of Pediatrics, Ataturk University, Erzurum</wicri:regionArea>
<wicri:noRegion>Erzurum</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Akat, Hulya" sort="Akat, Hulya" uniqKey="Akat H" first="Hulya" last="Akat">Hulya Akat</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Pediatrics, Ataturk University, Erzurum, Turkey.</nlm:affiliation>
<country xml:lang="fr">Turquie</country>
<wicri:regionArea>Department of Pediatrics, Ataturk University, Erzurum</wicri:regionArea>
<wicri:noRegion>Erzurum</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2021">2021</date>
<idno type="RBID">pubmed:33183365</idno>
<idno type="pmid">33183365</idno>
<idno type="doi">10.1017/S1047951120004291</idno>
<idno type="pmc">PMC7737124</idno>
<idno type="wicri:Area/Main/Corpus">000845</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000845</idno>
<idno type="wicri:Area/Main/Curation">000845</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000845</idno>
<idno type="wicri:Area/Main/Exploration">000845</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Effectiveness of lopinavir/ritonavir on COVID-19-related pneumonia in a child with COVID-19-associated Kawasaki disease.</title>
<author><name sortKey="Orbak, Zerrin" sort="Orbak, Zerrin" uniqKey="Orbak Z" first="Zerrin" last="Orbak">Zerrin Orbak</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Pediatrics, Ataturk University, Erzurum, Turkey.</nlm:affiliation>
<country xml:lang="fr">Turquie</country>
<wicri:regionArea>Department of Pediatrics, Ataturk University, Erzurum</wicri:regionArea>
<wicri:noRegion>Erzurum</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Laloglu, Fuat" sort="Laloglu, Fuat" uniqKey="Laloglu F" first="Fuat" last="Laloglu">Fuat Laloglu</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Pediatrics, Ataturk University, Erzurum, Turkey.</nlm:affiliation>
<country xml:lang="fr">Turquie</country>
<wicri:regionArea>Department of Pediatrics, Ataturk University, Erzurum</wicri:regionArea>
<wicri:noRegion>Erzurum</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Akat, Hulya" sort="Akat, Hulya" uniqKey="Akat H" first="Hulya" last="Akat">Hulya Akat</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Pediatrics, Ataturk University, Erzurum, Turkey.</nlm:affiliation>
<country xml:lang="fr">Turquie</country>
<wicri:regionArea>Department of Pediatrics, Ataturk University, Erzurum</wicri:regionArea>
<wicri:noRegion>Erzurum</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">Cardiology in the young</title>
<idno type="eISSN">1467-1107</idno>
<imprint><date when="2021" type="published">2021</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Ampicillin (therapeutic use)</term>
<term>Anti-Bacterial Agents (therapeutic use)</term>
<term>Anticoagulants (therapeutic use)</term>
<term>Antiviral Agents (therapeutic use)</term>
<term>Azithromycin (therapeutic use)</term>
<term>COVID-19 (complications)</term>
<term>COVID-19 (diagnostic imaging)</term>
<term>COVID-19 (drug therapy)</term>
<term>COVID-19 (physiopathology)</term>
<term>COVID-19 Nucleic Acid Testing (MeSH)</term>
<term>COVID-19 Serological Testing (MeSH)</term>
<term>Child (MeSH)</term>
<term>Drug Combinations (MeSH)</term>
<term>Enoxaparin (therapeutic use)</term>
<term>Humans (MeSH)</term>
<term>Hydroxychloroquine (therapeutic use)</term>
<term>Hypoxia (etiology)</term>
<term>Hypoxia (physiopathology)</term>
<term>Hypoxia (therapy)</term>
<term>Immunoglobulins, Intravenous (therapeutic use)</term>
<term>Immunologic Factors (therapeutic use)</term>
<term>Lopinavir (therapeutic use)</term>
<term>Lung (diagnostic imaging)</term>
<term>Male (MeSH)</term>
<term>Mucocutaneous Lymph Node Syndrome (drug therapy)</term>
<term>Mucocutaneous Lymph Node Syndrome (etiology)</term>
<term>Mucocutaneous Lymph Node Syndrome (physiopathology)</term>
<term>Oseltamivir (therapeutic use)</term>
<term>Oxygen Inhalation Therapy (MeSH)</term>
<term>Ritonavir (therapeutic use)</term>
<term>Sulbactam (therapeutic use)</term>
<term>Tomography, X-Ray Computed (MeSH)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Ampicilline (usage thérapeutique)</term>
<term>Antibactériens (usage thérapeutique)</term>
<term>Anticoagulants (usage thérapeutique)</term>
<term>Antiviraux (usage thérapeutique)</term>
<term>Association médicamenteuse (MeSH)</term>
<term>Azithromycine (usage thérapeutique)</term>
<term>Enfant (MeSH)</term>
<term>Facteurs immunologiques (usage thérapeutique)</term>
<term>Humains (MeSH)</term>
<term>Hydroxychloroquine (usage thérapeutique)</term>
<term>Hypoxie (physiopathologie)</term>
<term>Hypoxie (thérapie)</term>
<term>Hypoxie (étiologie)</term>
<term>Immunoglobulines par voie veineuse (usage thérapeutique)</term>
<term>Lopinavir (usage thérapeutique)</term>
<term>Maladie de Kawasaki (physiopathologie)</term>
<term>Maladie de Kawasaki (traitement médicamenteux)</term>
<term>Maladie de Kawasaki (étiologie)</term>
<term>Mâle (MeSH)</term>
<term>Oséltamivir (usage thérapeutique)</term>
<term>Oxygénothérapie (MeSH)</term>
<term>Poumon (imagerie diagnostique)</term>
<term>Ritonavir (usage thérapeutique)</term>
<term>Sulbactam (usage thérapeutique)</term>
<term>Tomodensitométrie (MeSH)</term>
<term>Énoxaparine (usage thérapeutique)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Ampicillin</term>
<term>Anti-Bacterial Agents</term>
<term>Anticoagulants</term>
<term>Antiviral Agents</term>
<term>Azithromycin</term>
<term>Enoxaparin</term>
<term>Hydroxychloroquine</term>
<term>Immunoglobulins, Intravenous</term>
<term>Immunologic Factors</term>
<term>Lopinavir</term>
<term>Oseltamivir</term>
<term>Ritonavir</term>
<term>Sulbactam</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>COVID-19</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnostic imaging" xml:lang="en"><term>COVID-19</term>
<term>Lung</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>COVID-19</term>
<term>Mucocutaneous Lymph Node Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Hypoxia</term>
<term>Mucocutaneous Lymph Node Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="imagerie diagnostique" xml:lang="fr"><term>Poumon</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathologie" xml:lang="fr"><term>Hypoxie</term>
<term>Maladie de Kawasaki</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>COVID-19</term>
<term>Hypoxia</term>
<term>Mucocutaneous Lymph Node Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Hypoxia</term>
</keywords>
<keywords scheme="MESH" qualifier="thérapie" xml:lang="fr"><term>Hypoxie</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Maladie de Kawasaki</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Ampicilline</term>
<term>Antibactériens</term>
<term>Anticoagulants</term>
<term>Antiviraux</term>
<term>Azithromycine</term>
<term>Facteurs immunologiques</term>
<term>Hydroxychloroquine</term>
<term>Immunoglobulines par voie veineuse</term>
<term>Lopinavir</term>
<term>Oséltamivir</term>
<term>Ritonavir</term>
<term>Sulbactam</term>
<term>Énoxaparine</term>
</keywords>
<keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Hypoxie</term>
<term>Maladie de Kawasaki</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>COVID-19 Nucleic Acid Testing</term>
<term>COVID-19 Serological Testing</term>
<term>Child</term>
<term>Drug Combinations</term>
<term>Humans</term>
<term>Male</term>
<term>Oxygen Inhalation Therapy</term>
<term>Tomography, X-Ray Computed</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Association médicamenteuse</term>
<term>Enfant</term>
<term>Humains</term>
<term>Mâle</term>
<term>Oxygénothérapie</term>
<term>Tomodensitométrie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The large outbreak of coronavirus disease 2019 (COVID-19) is spreading all over the world rapidly. There have recently been publications in the literature regarding the relationship between COVID-19 and Kawasaki disease, but there is no sufficient knowledge about the treatment and follow-up.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33183365</PMID>
<DateCompleted><Year>2021</Year>
<Month>03</Month>
<Day>18</Day>
</DateCompleted>
<DateRevised><Year>2021</Year>
<Month>03</Month>
<Day>18</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1467-1107</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>31</Volume>
<Issue>3</Issue>
<PubDate><Year>2021</Year>
<Month>Mar</Month>
</PubDate>
</JournalIssue>
<Title>Cardiology in the young</Title>
<ISOAbbreviation>Cardiol Young</ISOAbbreviation>
</Journal>
<ArticleTitle>Effectiveness of lopinavir/ritonavir on COVID-19-related pneumonia in a child with COVID-19-associated Kawasaki disease.</ArticleTitle>
<Pagination><MedlinePgn>507-510</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1017/S1047951120004291</ELocationID>
<Abstract><AbstractText>The large outbreak of coronavirus disease 2019 (COVID-19) is spreading all over the world rapidly. There have recently been publications in the literature regarding the relationship between COVID-19 and Kawasaki disease, but there is no sufficient knowledge about the treatment and follow-up.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Orbak</LastName>
<ForeName>Zerrin</ForeName>
<Initials>Z</Initials>
<Identifier Source="ORCID">https://orcid.org/0000-0002-1847-9844</Identifier>
<AffiliationInfo><Affiliation>Department of Pediatrics, Ataturk University, Erzurum, Turkey.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Laloglu</LastName>
<ForeName>Fuat</ForeName>
<Initials>F</Initials>
<AffiliationInfo><Affiliation>Department of Pediatrics, Ataturk University, Erzurum, Turkey.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Akat</LastName>
<ForeName>Hulya</ForeName>
<Initials>H</Initials>
<AffiliationInfo><Affiliation>Department of Pediatrics, Ataturk University, Erzurum, Turkey.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>11</Month>
<Day>13</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Cardiol Young</MedlineTA>
<NlmUniqueID>9200019</NlmUniqueID>
<ISSNLinking>1047-9511</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D017984">Enoxaparin</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016756">Immunoglobulins, Intravenous</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007155">Immunologic Factors</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C558899">lopinavir-ritonavir drug combination</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>20O93L6F9H</RegistryNumber>
<NameOfSubstance UI="D053139">Oseltamivir</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>2494G1JF75</RegistryNumber>
<NameOfSubstance UI="D061466">Lopinavir</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber>
<NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>65DT0ML581</RegistryNumber>
<NameOfSubstance UI="C035444">sultamicillin</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>7C782967RD</RegistryNumber>
<NameOfSubstance UI="D000667">Ampicillin</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>83905-01-5</RegistryNumber>
<NameOfSubstance UI="D017963">Azithromycin</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>O3J8G9O825</RegistryNumber>
<NameOfSubstance UI="D019438">Ritonavir</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>S4TF6I2330</RegistryNumber>
<NameOfSubstance UI="D013407">Sulbactam</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000667" MajorTopicYN="N">Ampicillin</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017963" MajorTopicYN="N">Azithromycin</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
<QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000087123" MajorTopicYN="N">COVID-19 Nucleic Acid Testing</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000087124" MajorTopicYN="N">COVID-19 Serological Testing</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017984" MajorTopicYN="N">Enoxaparin</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000860" MajorTopicYN="N">Hypoxia</DescriptorName>
<QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
<QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016756" MajorTopicYN="N">Immunoglobulins, Intravenous</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007155" MajorTopicYN="N">Immunologic Factors</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D061466" MajorTopicYN="N">Lopinavir</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName>
<QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009080" MajorTopicYN="N">Mucocutaneous Lymph Node Syndrome</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
<QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053139" MajorTopicYN="N">Oseltamivir</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010102" MajorTopicYN="Y">Oxygen Inhalation Therapy</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019438" MajorTopicYN="N">Ritonavir</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013407" MajorTopicYN="N">Sulbactam</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014057" MajorTopicYN="N">Tomography, X-Ray Computed</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword>
<Keyword MajorTopicYN="N">Kawasaki disease</Keyword>
<Keyword MajorTopicYN="N">pneumonia</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>11</Month>
<Day>14</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2021</Year>
<Month>3</Month>
<Day>19</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>11</Month>
<Day>13</Day>
<Hour>5</Hour>
<Minute>33</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">33183365</ArticleId>
<ArticleId IdType="pii">S1047951120004291</ArticleId>
<ArticleId IdType="doi">10.1017/S1047951120004291</ArticleId>
<ArticleId IdType="pmc">PMC7737124</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Turquie</li>
</country>
</list>
<tree><country name="Turquie"><noRegion><name sortKey="Orbak, Zerrin" sort="Orbak, Zerrin" uniqKey="Orbak Z" first="Zerrin" last="Orbak">Zerrin Orbak</name>
</noRegion>
<name sortKey="Akat, Hulya" sort="Akat, Hulya" uniqKey="Akat H" first="Hulya" last="Akat">Hulya Akat</name>
<name sortKey="Laloglu, Fuat" sort="Laloglu, Fuat" uniqKey="Laloglu F" first="Fuat" last="Laloglu">Fuat Laloglu</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000531 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000531 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= CovidChloroV1 |flux= Main |étape= Exploration |type= RBID |clé= pubmed:33183365 |texte= Effectiveness of lopinavir/ritonavir on COVID-19-related pneumonia in a child with COVID-19-associated Kawasaki disease. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:33183365" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \ | NlmPubMed2Wicri -a CovidChloroV1
This area was generated with Dilib version V0.6.38. |